Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fresenius Medical Care ( (FMS) ) has issued an update.
On May 5, 2026, Fresenius Medical Care reported first-quarter 2026 results showing 4% organic revenue growth at constant currency and a 10% rise in adjusted operating income, expanding its adjusted margin to 10.1%. The company highlighted strong performance in its Care Delivery segment, supported by favorable U.S. reimbursement under TDAPA and the rapid U.S. rollout of its 5008X CAREsystem, now in about 100 clinics with more than 100,000 treatments performed.
Despite this operational progress, reported operating income fell 14% and net income dropped 22% due to EUR 166 million in one-time costs from the FME25+ transformation program, which includes closing 64 of up to 100 U.S. clinics while aiming to retain most patients in neighboring sites. Fresenius Medical Care also accelerated a EUR 1.0 billion share buyback, repurchasing 24.8 million shares, and reiterated its full-year 2026 outlook, underscoring confidence in its FME Reignite strategy to strengthen margins and deliver EUR 1.2 billion in savings by 2027.
The most recent analyst rating on (FMS) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Fresenius Medical Care stock, see the FMS Stock Forecast page.
Spark’s Take on FMS Stock
According to Spark, TipRanks’ AI Analyst, FMS is a Neutral.
The score reflects moderate fundamentals with improving profitability and a stable balance sheet but weakening growth/cash-flow trends, a cautious 2026 outlook with meaningful headwinds despite strong execution initiatives, and a supportive valuation (modest P/E and solid dividend) alongside neutral-to-soft technical momentum.
To see Spark’s full report on FMS stock, click here.
More about Fresenius Medical Care
Fresenius Medical Care AG is a German-based global leader in dialysis, providing products and services for individuals with chronic kidney and renal disease. The group operates across Care Delivery, Value-Based Care and Care Enablement segments, with a strong focus on U.S. and international dialysis clinics and on rolling out its 5008X CAREsystem technology worldwide.
Average Trading Volume: 568,222
Technical Sentiment Signal: Sell
Current Market Cap: $13.2B
For detailed information about FMS stock, go to TipRanks’ Stock Analysis page.